Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (177)	5/13/1998 4:38:00 PM
From: Jay Lowe	Read Replies (2) \| Respond to of 586

The Plan - Jay enrolls CYPB in the process (Hall, Blank) - MuddPhudd talks to Blank (or whoever) - MuddPhudd creates technical notes on Prosorba techology and applications near-term and going forward - MuddPhudd talks to Nepom (Virgina Mason) and Sasso (U Wash) - MuddPhudd reviews CYPB scientific protocol - Jay creates web page(s) containing above notes - Jay pulls together company information scattered around onto web - We find a financial/business person (BizWiz) to participate - BizWiz reviews financials and projections - Jay puts up website "Cypress Investor's Group" with above - good possibility to get professional web design without cost - we post website URL to this thread every 10 messages or 3 days Result: a shiny website with all the company information at the fingertips of all who are interested. Benefit: confidence level for us; fun; increased valuation; profit

To: muddphudd who wrote (177)	5/15/1998 4:55:00 AM
From: John S. Baker	Respond to of 586

> Do you think that CYPB needs to figure out the mechanism of action by the column for FDA approval?? < My hunch is that the answer is no ... no need to figure it out before FDA approval. Reason: if CYPB thought it necessary, there would be evidence of panic-stricken effort to complete the research. Instead, it appears orderly and normal (at least normal for a bio-tech firm). I attended an investors briefing by Dr. Kranzler in January and he described the "how it works" research in very matter-of-fact tones. I did not record that session so cannot give a verbatim.